SABCS23 Day 3 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the third day’s highlights from X/Twitter.
”SABCS23 Day 3 Highlights Community Oncology:
1. TROPIONBreast01.
2. Optimizing XRT and Surgery in early BC.
3. Pregnancy after breast ca diagnosis.
1. TROPION Breast01: DatoDXd Vs Chemo post 1-2L in HR+ mBC
– time to 1st Rx: 8.2 vs 5mos (HR: 0.53, favoring Dato),
– Better AE + QoL with DatoDXd,
– higher PFS at ESMO23. Pending OS. Very likely to get approved and be in the same space as Sacituzumab.
For the more information click here.
2. Optimizing Surgery and XRT:
– low staging nodal status (cN+ to ypN0) w/ NACT can optimize adj XRT,
– ALND improved local regional recurrence (but this risk is low to begin with). mortality benefit. Higher lymphedema,
– XRT can be safely in HR+ postmenopausal low risk Stage I.
For the more information click here.
3. Pregnancy w/ Breast Cancer diagnosis:
– POSITIVE Ann Partridge: most pts w/ amenorrhea resumed menses when endocrine Rx was interrupted,
– Young age associated w/ shorter time to pregnancy,
– Analysis by Matteo Lambertini showed low complications even w/gBRCA pts.
For the more information click here.”
Source: Oncology Brothers/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023